Adaptimmune Therapeutics PLC: Nasdaq/NYSE listing notice — Adaptimmune receives Nasdaq deficiency notice for ADS bid price below $1.00; 180-day cure period ends Feb 27, 2024

Adaptimmune Therapeutics PLC

Received Nasdaq notice on Aug 31, 2023 for non-compliance with minimum bid price of $1.00 per ADS for 30 consecutive business days.
Has 180 calendar days, until February 27, 2024, to regain compliance by closing at $1.00 for ten consecutive business days.
If not compliant by Feb 27, may transfer to Nasdaq Capital Market for additional 180-day period subject to other standards.
Company intends to monitor bid price and assess actions; no immediate effect on listing or trading.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

August 31, 2023, Adaptimmune Therapeutics plc (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), because the minimum bid price of the Company’s American Depositary Shares (“ADSs”) has been below $1.00 per share for 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing or trading of the Company’s ADSs on The Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until February 27, 2024, to

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-015390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.